These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 30509601)

  • 41. Assessment of Liver Disease Progression in Cystic Fibrosis Using Transient Elastography.
    Gominon AL; Frison E; Hiriart JB; Vergniol J; Clouzeau H; Enaud R; Bui S; Fayon M; de Ledinghen V; Lamireau T
    J Pediatr Gastroenterol Nutr; 2018 Mar; 66(3):455-460. PubMed ID: 29112089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum proteome profiling identifies novel and powerful markers of cystic fibrosis liver disease.
    Rath T; Hage L; Kügler M; Menendez Menendez K; Zachoval R; Naehrlich L; Schulz R; Roderfeld M; Roeb E
    PLoS One; 2013; 8(3):e58955. PubMed ID: 23516586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis.
    Shen F; Mi YQ; Xu L; Liu YG; Wang XY; Pan Q; Zhang RN; Hu XQ; Xu LM; Fan JG
    Aliment Pharmacol Ther; 2019 Jul; 50(1):93-102. PubMed ID: 31094016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosis-Associated Liver Disease.
    Freeman AJ; Sellers ZM; Mazariegos G; Kelly A; Saiman L; Mallory G; Ling SC; Narkewicz MR; Leung DH
    Liver Transpl; 2019 Apr; 25(4):640-657. PubMed ID: 30697907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. When the liver gets stiff, the tough get moving.
    Nguyen TH; Wardell R; Chitturi S; Teoh N; Farrell G
    J Gastroenterol Hepatol; 2020 Jun; 35(6):953-959. PubMed ID: 31867782
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values.
    Petta S; Wong VW; Cammà C; Hiriart JB; Wong GL; Marra F; Vergniol J; Chan AW; Di Marco V; Merrouche W; Chan HL; Barbara M; Le-Bail B; Arena U; Craxì A; de Ledinghen V
    Hepatology; 2017 Apr; 65(4):1145-1155. PubMed ID: 27639088
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.
    Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Lee HW; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
    Aliment Pharmacol Ther; 2018 Apr; 47(7):989-1000. PubMed ID: 29446106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease.
    Ramírez-Vélez R; García-Hermoso A; Correa-Rodríguez M; Izquierdo M
    Pediatr Res; 2022 Mar; 91(4):912-920. PubMed ID: 33846557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.
    Lupșor-Platon M; Feier D; Stefănescu H; Tamas A; Botan E; Sparchez Z; Maniu A; Badea R
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):35-42. PubMed ID: 25822432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study.
    Klotter V; Gunchick C; Siemers E; Rath T; Hudel H; Naehrlich L; Roderfeld M; Roeb E
    PLoS One; 2017; 12(6):e0178784. PubMed ID: 28575039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating microRNAs as noninvasive diagnostic biomarkers of liver disease in children with cystic fibrosis.
    Cook NL; Pereira TN; Lewindon PJ; Shepherd RW; Ramm GA
    J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):247-54. PubMed ID: 25625579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years.
    Zeng J; Zhang X; Sun C; Pan Q; Lu WY; Chen Q; Huang LS; Fan JG
    BMC Pediatr; 2019 Apr; 19(1):129. PubMed ID: 31018838
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SERPINA1 Z allele is associated with cystic fibrosis liver disease.
    Boëlle PY; Debray D; Guillot L; Corvol H;
    Genet Med; 2019 Sep; 21(9):2151-2155. PubMed ID: 30739910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan.
    Cho Y; Tokuhara D; Morikawa H; Kuwae Y; Hayashi E; Hirose M; Hamazaki T; Tanaka A; Kawamura T; Kawada N; Shintaku H
    PLoS One; 2015; 10(9):e0137239. PubMed ID: 26398109
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Usefulness of Controlled Attenuation Parameter and Liver Stiffness Measurement for the Identification of Extended-criteria Donors and Risk-assessment in Liver Transplantation.
    Duarte-Rojo A; Heimbach JK; Borja-Cacho D; Barone GW; Shaheen MF; Lamps LW; Graham RP; Tan EK; Concepcion W; Kim WR
    Transplantation; 2022 Feb; 106(2):318-327. PubMed ID: 33675319
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.
    Pereira TN; Lewindon PJ; Smith JL; Murphy TL; Lincoln DJ; Shepherd RW; Ramm GA
    J Hepatol; 2004 Oct; 41(4):576-83. PubMed ID: 15464237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography.
    Yilmaz Y; Ergelen R; Akin H; Imeryuz N
    Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1330-4. PubMed ID: 23660937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of Liver Fibrosis with the Use of Elastography in Paediatric Patients with Diagnosed Cystic Fibrosis.
    Wiecek S; Fabrowicz P; Wos H; Kordys-Darmolinska B; Cebula M; Gruszczynska K; Grzybowska-Chlebowczyk U
    Dis Markers; 2022; 2022():4798136. PubMed ID: 35345868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY.
    Paul J; Venugopal RV; Peter L; Shetty KNK; Shetti MP
    Arq Gastroenterol; 2018; 55(1):7-13. PubMed ID: 29561981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.